Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | SWOG S1216: ADT and TAK700 in prostate cancer

Shilpa Gupta, MD, Cleveland Clinic, Cleveland, OH, discusses the updated results of the SWOG S1216 trial (NCT01809691): a Phase III trial comparing the safety and efficacy of androgen deprivation therapy (ADT) and the 17,20-lyase inhibitor TAK-700 with ADT and bicalutamide in patients with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC). TAK-700 significantly reduced progression by 42% and led to better prostate-specific antigen (PSA) responses; 14% more patients achieved a complete response, compared to the bicalutamide group. However adverse events (AEs) were increased in the TAK-700 group and although the improvement in overall survival (OS) in the TAK-700 group, 11 months, was clinically significant, it was not enough to be considered statistically significant; the OS in the control group was the highest ever recorded in such a trial. These findings provide a new benchmark for survival estimates in future trials. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.


Shilpa Gupta, MD has consultancy fees from Merck, Pfizer, Seattle Genetics, BMS, and Astrazeneca.